Analyst Update: Five Below, Myriad Genetics, Charles Schwab

Analysts are weighing in today on retailer Five Below Inc (NASDAQ:FIVE), molecular diagnostics firm Myriad Genetics, Inc. (NASDAQ:MYGN), and savings-and-loan issue Charles Schwab Corp (NYSE:SCHW). Here's a quick look at today's brokerage notes on FIVE, MYGN, and SCHW.

• Following last night's fourth-quarter earnings beat, the shares of FIVE are up nearly 11% to reach $35.75, reducing their year-to-date deficit to 12.4%. In response, no fewer than five brokerage firms revised their price targets on the equity, with the loftiest hike coming from Dougherty & Company, which raised its price target by $4 to $40. Meanwhile, Deutsche Bank Securities upped its target by $1 to $40, underscored a "buy" rating, and waxed optimistic on FIVE's new management team and long-term store growth potential. The largest cut came from Credit Suisse, which lowered its price target by $7 to $38. Looking back, the shares of Five Below Inc have been in recovery mode, up 25.4% from their March 10 two-year low of $28.51. Accordingly, calls have been popular in the options pits, as FIVE's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 4.92 ranks higher than 90% of all equivalent readings taken over the past year. Meanwhile, approximately 18.7% of the stock's available float is sold short, which would take nearly seven sessions to buy back, at average trading volumes.


• MYGN is following sector peer EXACT Sciences Corporation (NASDAQ:EXAS) lower this morning, after Goldman Sachs cut its rating to "sell" from "neutral" while lowering its price target by $6 to $25 -- in annual-low territory. At last check, the shares of Myriad Genetics, Inc. were down 3.1% to hit $35.06, reducing their year-to-date lead to 2.9%. Short sellers have taken a shine to MYGN, as roughly 45.7% of the stock's available float is sold short. What's more, it would take these speculators over 54 sessions to cover their bets, at the stock's average pace of trading.


• Barclays upgraded SCHW to "overweight" from "underweight" while raising its price target by $9 to $34 -- in terrain not charted in more than a decade -- sending the shares up 1.7% to reach $29.70. On the charts, Charles Schwab Corp has been trending upwards, with the shares gaining 27.2% since notching an annual low of $23.35 on Oct. 15. Additionally, the stock is presently spitting distance from its 14-year high of $31.73, tagged earlier this month. A good portion of the brokerage bunch is bearish on SCHW, though, as 62% of covering analysts rate the stock a "hold" or worse. Furthermore, the stock's average 12-month price target of $32.18 represents just an 8.4% premium to current trading levels. More upbeat analyst attention could propel SCHW even higher.